us afternoon Good and joining today. Ping. you, thank you Thank for
biotechnology the utilizing manufacturing bio feed, how we mission engineering. medicine, fuel modern and science, to world heal Our revolutionize and agriculture, improve is to by to transform
health markets manufacturing government to unmet together and income industry and drugs, We cost for by the biologic and protein the provide processes and growing scientific other community health and academia, to outputs solution the needs in increase human production products are vaccines address with bio and biologic lower for in satisfy demands inequity global help middle affordable can working a animal countries. and addressing that effective
just Phase key annual maintain protect vaccinations to a our about it still are my to means takeaway platform effort, believe while launch in at quantities We are human commercialization year and we the humans collaboration our new our Americas. been problem. be for in will XXXX advance likely towards to still further towards partnerships the XXXX which the candidate, attributes It animal clinical productive affordable proteins produce an continuing trial DYAI-XXX. require developments pharmaceutical efforts underdeveloped our The in continuation many their It the to important business the that has platform been of to COVID-XX our continue or trial it's of to a produce efforts of and proof-of-concept, technology. adoption. CX first mirror, today has production X was our use global scientific struggling a efforts development commercial CX protein announced COVID those a is prices Africa, accelerate advance critical many publishing and global where safe a to science in Asia, periodic antibody CX end. COVID, CX validate and comments platform effectiveness. data, soon in is protein are addition industries. and citizens. in-human boosters production important understand Many that we will people is as is sufficient advancing countries to of A rearview animal from very Europe, to further CX To relationships includes not and real vaccine
efficacy and just in humans, variant current CX safety the you Our drugs. important in safety would to several There I be DYAI-XXX X vaccines and happens Rubic main commenced, gating for. other applications indications can focus. been we Phase transfer be our to consortium can collaborations. numerous updates many is for other CX so used have delivered. an brief like to some in platform other event. are COVID CX all pursue The ongoing interested Demonstrating and the has the on is give technology in our and platform COVID-XX the that demonstrate objective countries RBDs
tools, In cells transferred. human and addition, been cells producing also from and engineering CX for genetic has protocols proteins trainings sub
successfully in regarding addition Syngene training where We other been can has CX are vaccine manufacturing several line cell of with discussion development the technology transfer technology International of CX and and completed, they production completed tech the number the part the variants delivered. and RBD accelerated developing commercialization COVID-XX platform nanoparticle RBD has transfer to COVID apply in DYAI-XXX to including Rubic on of vaccine COVID-XX concern, the Delta for CX the platform servers initial talks variants. they shown candidates has been success been has tech a of the for are Many candidates. antigens,
DYAI-XXX safety for GLP those profile of have for the will one or materially in product can been drug drug vaccine for is carrying a be different clinical terms give DYAI-XXX. initiated. acceptance, has Sorrento to of will platform license out been immunoglobulin licence demonstrated RBD for detected the into specific DYAI-XXX converted regulatory A Israel, the may maybe our XXXX. XX be week binding IgG Therapeutics study the we preliminary set vaccine when no which virus Israel, be no pharmaceutical has agreement by faring in CX continuing negotiate using which than after animal will August sheet be interim a executed what produced more terms in General Bio-Technology anticipate X X have company X SARS-CoV- toxicology SARS-CoV- DYAI-XXX CX Sorrento the technology and the Phase trials. This transfer animals. candidate We purification have agreement the guidance a a successful announced antibodies here term forth substance, and in the -- in
producing cells to a antibodies. manufacture had of show CX demonstrate of the monoclonal and costs. focus to monoclonal that to CX specifics other high and to and can proof both and continues Nivolumab use continue on yield for used glycosylated lower be faster concept towards progress a Multi biomolecule but glycoengineering the proteins antibodies, other We
and mice. production manufacturing cell express Now, successfully antigen vaccines. published I'd showed Anticipation efficacy was was validated particle-display The for were June, antigens. ZAPI like study CX animal for in successfully CX a to antigens journal. and peer-reviewed and recombinant develop used safety, The ongoing CX July to our SBV concluded Zoonoses The effective drugs cattle, protection program in the to is Preparedness in vaccines, the and efforts Initiative, In CX provide XXXX. RVFV health. in express sheep a scientific update on ZAPI brief using use vaccines platform ZAPI, protein SBV produced and leading most
encouraging poultry on work results those of a how our more fully productivity company farm promising The a animals. further produced collaboration to the antigens antigens. project We additional is global or on to determine Based these commercial using this to in of to studies. conducting antigens portion health funded for animal trials, expand discussions potential animal are antigens. to-date, one we are for CX We increasing efficacy of continuing with X demonstrating that in began Phase work CX are
in global markets, human technology markets. is with accelerating. working These expertise, broad with potential conjunction interest animal nutraceuticals, animal our potential markets in and health and also underscores companion to other that cosmetics, our markets, are decades non-pharmaceutical company experience food, of to are applications in antibody. focus we We we biotech current as animal in experiencing health well and knowledge two in The exploring CX a plus as industrial another develop are applying agricultural, inbound applying of
growth Our iterative process. been an has
to case, an not company collaborating an or is As a name able the partner. often announcement make has the been
we've on, activity up made in traction every especially production and the where to smaller regions, distribution physical gaining easy and and and are geographical with However, footprints set are announced vaccine we and working lacking necessary. mission executing and facilities where new across science on to drug on tooling, are we life flexible, Based do to clearly use, collaboration industries, so where are possible. level effort commercial the of our we've manufacturing
positioned to these situations. We deal are with uniquely
our We as many are bear fruit development a at a head are critical to starting operational efforts point in lifecycle, across company's regarding corporate the nearing otherwise and to outcomes. initiatives or
clear create a bio COVID, shift, As manufacturing much biologics, activity just well our capabilities better And but pandemic. a whose around tension results related, CX technology could for and decades transform benefits global our been on operating once-in-a-generation a come. need started production of production animal the the to of vaccines, COVID-XX technology platform, health before story to not the for journey as the for in has is human play Dyadic’s
and as plan, strategic well We and a have operating a as capital strategy. appropriate allocation clear resources
regulatory a Our the into Getting company's X a we COVID-XX first platform. apply has Phase commercial licensed the explore science edge joined to next regulatory leadership Dyadic including expression order company's licensing, and over continues is pursue at opportunities, candidate continue has expired and agreement key team. commercialization new existing protein to years XX critically proprietary previously commercialization to health joins Dyadic DuPont, where applications. development, comes CX be including the manufacturing important and business human He management, and supporting welcome additional activity a CX our Chief Joe Novartis. XX business our a development business commercial pleased focus years executive to the going us opportunities mentioned with oversight of outside critical Hazelton as our new closing to expand non-compete to of Joe experience further Officer. out to that global and I and to of point is human been initiatives, allowing clinical of animal Joe vaccine DYAI-XXX development, Business Joe's global forward. of technology matters. a in portfolio in to I'm our experience, step. application with to with cutting Sciences as and trial
broad produce than Our of CX culmination of more scale. biofuel. enzymes ongoing cross production application to reliably needed industries, a efficiency, proven transformed in industries years research, well scale have advances XX to those of and Dyadic’s development ranging production evolution had production, ultimately is and as enzyme manufacturing development, the and such footprint protein industrial as industrial proteins platform for scalability, as
benefit of opportunity an now the enormous turn number We've committed opportunities on those the to that best it will before is CX platform technology we're toward maximize update. doing the resources. financial our it to call We monetize our limited for Ping for over of and shareholders. done working present Management I have focusing again. to to
